Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002157 · ClinicalTrials.gov registry record · NA
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
A NA study, sponsored by Celgene Corporation.
- Completed
- Registry status
- NA
- Development phase
NCT00002157: Completed NA study, sponsored by Celgene Corporation.
NCT00002157 is a NA study that has completed, run by Celgene Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002157, a NA study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal placebo-controlled study.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002157 record still lists
NCT00002157 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00002157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002157 about?
NCT00002157 is a clinical study titled "Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome". To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal placebo-controlled study.
What is the current status of trial NCT00002157?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002157?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00002157?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.